Hereditary Paraganglioma-Pheochromocytoma Syndromes (PGL/PCC) [MONDO:0017366, PMID: 20301715] are associated with an increased risk of multiple paragangliomas and pheochromocytomas tumors within multiple organ systems transmitted in autosomal dominant inheritance. The molecular mechanism is loss of function in one of the 4 genes comprising the succinate dehydrogenase and SDHAF gene for flavination of SDHA, as well as stabilization of the SDH complex. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism, inheritance pattern and phenotypic variability. Therefore, this is a lumping Curation for SDHD and SDHD associated Hereditary Paraganglioma-Pheochromocytoma syndromes (PGL/PCC) including autosomal dominant inherited Paraganglioma 1 with or without deafness (MIM: 168000) and Pheochromocytoma (MIM: 171300). The autosomal recessive inherited Mitochondrial Complex II Deficiency (MIM: 252011) will be curated separately. SDHD encodes one of the subunits of SDH (succinate dehydrogenase), a component of complex II in mitochondria. It was the first tumor suppressor gene identified as encoding a mitochondrial protein. SDHD was first reported in relation to PGL/PCC in 2000 [Baysal et al., PMID: 10657297]. Two missense variants and seven nonsense variants from two large studies [PMID: 16317055 and 12000816] are included in this curation. Maternal transmission has been rarely reported and Dutch founder variants are recorded [PMIDs: 19584903, 11391798 and PMID: 15010701]. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. Experimental evidence showed absent or decreased expression of SDHB, the iron protein, catalytic component of mitochondrial complex II [PMIDs: 19576851, 20236688 and 14595761], and absent or decreased SDH enzyme activity [PMIDs 14595761 and 15652751] in human SDHD related tumors. There was no mouse model available as homozygous sdhd KO mice are embryonically lethal and heterozygous mice do not develop any tumors [PMIDs: 19956719, 15572694]. Biochemical studies on accumulated succinate due to reduced SDH activity and succinated induced pseudo-hypoxic drive, i.e., stabilization of HIF1a, inhibition of HIF prolyl hydroxylases are repetitively reported [PMIDs: 26971832, 17102089, 15987702]; in addition, SDHD related up-regulation of the p21WAF1/Cip1 in liver and kidney of the conditional tamoxifen-inducible SDHD-ESR mutant mice and two immortalized SDHD-ESR cell lines are also reported. The p21 is implicated in many biological processes including cell cycle, survival, and cancer [PMID: 24465590]. A truncated hSDHD mutant, W105X (previously W66X), expressed in immortalized Chinese hamster lung fibroblast model showed increased genomic instability mediated by increased ROS [PMID: 22041456]. In summary, the SDHD gene is definitely associated with autosomal dominant HPGL/PCC syndrome. This has been repeatedly demonstrated in both the genetic, and experimental, biochemical and functional studies, and has been upheld over time.
The GenCC data are available free of restriction under a CC0 1.0 Universal (CC0 1.0) Public Domain Dedication. The GenCC requests that you give attribution to GenCC and the contributing sources whenever possible and appropriate. The accepted Flagship manuscript is now available from Genetics in Medicine (https://www.gimjournal.org/article/S1098-3600(22)00746-8/fulltext).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The GenCC does not independently verify the submitted information. Though the information is obtained from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis, collected through periodic submission and therefore may not represent the most up-to-date information from the submitters. If you have questions about the medical relevance of information contained on this website, please see a healthcare professional; if you have questions about specific gene-disease claims, please contact the relevant sources; and if you have questions about the representation of the data on this website, please contact gencc@thegencc.org.